Benchmark Reiterates Buy on Ligand Pharmaceuticals, Maintains $95 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Robert Wasserman reiterates a Buy rating on Ligand Pharmaceuticals (LGND) and maintains a $95 price target.
April 12, 2024 | 1:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst reiterates a Buy rating on Ligand Pharmaceuticals with a $95 price target.
The reiteration of a Buy rating and maintenance of a $95 price target by a Benchmark analyst suggests a positive outlook for Ligand Pharmaceuticals, likely leading to increased investor confidence and potential upward movement in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100